secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2023-07-07T23:59:59+00:00
Accession:  0001493152-23-023908
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona closes $25M direct offering; proceeds to fund EB-101 commercialization
-----------------------------------------------------------------------------

- Gross proceeds of $25M from sale of 3.28M shares and 2.92M pre-funded warrants at $4.03 per share.
- Offering led by Nantahala Capital Management with participation by Adage Capital Partners and other existing investors.
- Net proceeds to fund commercialization of EB-101 and extend cash runway into Q4 2024.
- Company expects to qualify for a priority review voucher upon potential BLA approval in H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315223023908/0001493152-23-023908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315223023908/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-023908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer